China Biologic Products Holdings, Inc. (CBPO) Shares Bought by California Public Employees Retirement System

California Public Employees Retirement System increased its holdings in shares of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) by 51.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,757 shares of the biopharmaceutical company’s stock after acquiring an additional 15,257 shares during the period. California Public Employees Retirement System’s holdings in China Biologic Products were worth $4,130,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CBPO. Hillhouse Capital Management Ltd. grew its position in China Biologic Products by 186.8% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 753,624 shares of the biopharmaceutical company’s stock worth $85,235,000 after acquiring an additional 490,874 shares during the last quarter. Schroder Investment Management Group grew its position in China Biologic Products by 86.5% during the 3rd quarter. Schroder Investment Management Group now owns 1,016,092 shares of the biopharmaceutical company’s stock worth $92,799,000 after acquiring an additional 471,416 shares during the last quarter. Macquarie Group Ltd. grew its position in China Biologic Products by 115.3% during the 2nd quarter. Macquarie Group Ltd. now owns 587,587 shares of the biopharmaceutical company’s stock worth $66,456,000 after acquiring an additional 314,700 shares during the last quarter. Artisan Partners Limited Partnership grew its position in China Biologic Products by 62.9% during the 3rd quarter. Artisan Partners Limited Partnership now owns 723,859 shares of the biopharmaceutical company’s stock worth $66,790,000 after acquiring an additional 279,420 shares during the last quarter. Finally, Comgest Global Investors S.A.S. grew its position in China Biologic Products by 135.0% during the 3rd quarter. Comgest Global Investors S.A.S. now owns 356,252 shares of the biopharmaceutical company’s stock worth $32,872,000 after acquiring an additional 204,649 shares during the last quarter. Institutional investors and hedge funds own 65.13% of the company’s stock.

A number of equities research analysts recently commented on the company. Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a research report on Wednesday, November 15th. BidaskClub upgraded China Biologic Products from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. China Biologic Products currently has an average rating of “Hold” and a consensus target price of $137.50.

China Biologic Products Holdings, Inc. (NASDAQ CBPO) opened at $79.26 on Thursday. The company has a market capitalization of $2,730.00, a price-to-earnings ratio of 20.64, a price-to-earnings-growth ratio of 1.00 and a beta of 1.79. China Biologic Products Holdings, Inc. has a 12-month low of $72.21 and a 12-month high of $120.46.

WARNING: This piece was posted by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.themarketsdaily.com/2018/01/11/china-biologic-products-holdings-inc-cbpo-shares-bought-by-california-public-employees-retirement-system.html.

China Biologic Products Company Profile

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products Holdings, Inc. (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply